expressed in a "fetal gene program" (3) . Consistent with this paradigm, pressure overload, volume overload, ischemic damage, and other naturally occurring events that stimulate cardiac hypertrophy are associated with increased expression of embryonic cardiac genes such as atrial natriuretic peptide (ANP), ␤-myosin heavy chain (␤MHC), and ␣-skeletal actin (2, 6, 10) . Increased levels of these mRNAs have also been reported in some artificial forms of cardiac hypertrophy and heart failure created by manipulation of the mouse genome (4, 11, 18) . Based on the apparent ubiquity with which these genes are upregulated in hypertrophied and failing ventricles, it has been hypothesized that the products of these genes could contribute mechanistically to these cardiac syndromes, and pathological roles for each have been proposed (15, 16, 25) . The logical foundation for assigning pathological significance to hypertrophy-associated gene products relies on the existence of a de facto hypertrophy gene program, i.e., a distinct group of genes that constitute a molecular program encoding the developmental process and/or ultimate features of myocardial hypertrophy. However, progress toward elucidating such a unified molecular program is challenged by recently described genetically modified mouse models of hypertrophy in which reexpression of embryonic cardiac genes can be dissociated from hypertrophy (4, 17, 18, 21, 23) . In these genetically induced models, cardiac hypertrophy is transduced through multiple parallel and/or redundant signaling pathways, which suggests that hypertrophy could be encoded through multiple genetic pathways. These phenotypically similar, but pathophysiologically dissimilar genetic hypertrophy models therefore constitute a set of biological reagents uniquely suited for evaluating molecular determinants of myocardial hypertrophy through comparison of differentially expressed genes representing diverse functional groups.
In the current studies, DNA microarrays containing ϳ8,800 DNA sequences were used to compare gene expression changes in four transgenic mouse models of cardiac hypertrophy as a means of detecting the downstream consequences of a spectrum of hypertrophy Article published online before print. See web site for date of publication (http://physiolgenomics.physiology.org).signaling events by modified or overexpressed signaling proteins. Rather than defining a single gene program that encodes hypertrophy, the results suggest that hypertrophy-regulated genes are largely specific to the hypertrophy-inducing process. Thus, in contrast to the monolithic hypothesis, the uniqueness of modelspecific gene expression profiles suggests that expression profiling can give insight into individual pathophysiological characteristics of each hypertrophy model. In particular, we have identified a novel molecular program for cardiomyocyte apoptosis, as well as a small group of genes that do correlate with disease severity. Moreover, since the cardio-disruptive effects are largely unique to each transgene product, rather than marking a general transgenic overexpression stress response, further cross-comparisons of additional models may allow us to gain predictive capability into the genetic or etiologic origins of hypertrophic cardiomyopathy.
MATERIALS AND METHODS
Transgenic models. The G␣q-, calcineurin (CN)-, and calsequestrin (CSQ)-overexpressing mice and the protein kinase C-⑀ activation peptide (⌿⑀RACK) transgenic mouse have each been previously described (4, 17, 18, 21, 23) . In each of these mice, the full-length mouse ␣-MHC promoter (22) was used to drive cardiomyocyte-specific transgene expression on the FVB/N, or in CN mice B6C3F1, backgrounds. All mice used in the current studies (transgenic and nontransgenic littermates) were 8-wk-old males, except CN, which were 18 days old [because older CN mice progress to heart failure (18)]. Thus, in each case mice were used at an age where hypertrophy had developed without associated heart failure, i.e., in a state of nonfailing or "compensated" myocardial hypertrophy (defined as increased cardiac mass without pulmonary congestion). The mechanism for myocardial hypertrophy has been reported to be cardiomyocyte hypertrophy in G␣ q, CN, and CSQ and to be cardiomyocyte hyperplasia in ⌿⑀RACK (4, 17, 18, 20, 21) . Left ventricular mRNA was prepared using Trizol (GIBCO BRL; Life Technologies, Grand Island, NY) and the Oligotex mRNA isolation kit (Qiagen, Valencia, CA) according to manufacturer's instructions. Total RNA was passed twice through oligo-d(T) columns, and mRNA was stored as ethanolic precipitates at Ϫ70°C. To minimize variations attributable to individual mice and maximize differences attributable to their genotype, each experiment was performed with RNA pooled from 8-10 ventricles.
DNA microarray hybridization and analysis. DNA microarray hybridizations were performed using Incyte mouse gene expression microarray (GEM, version 1.12; Genome Systems, St. Louis, MO). For each model, a microarray was run using poly(A) ϩ mRNA from transgenic hearts vs. its corresponding nontransgenic control. Cy3 and Cy5 derivatized cDNA was prepared using random primers and reverse transcriptase. Fluorescent cDNAs were competitively hybridized to the DNA chips. Primary data were examined using Incyte Gemtools software and Silicon Genetics GeneSpring software. Defective cDNA spots (signal/noise ratio Ͻ2.5, irregular geometry, or Ͻ40% spot area compared with average) were eliminated from the data set of 8,799 sequence tags; 7,808 fit the criteria for inclusion in all four comparative experiments. Data sets were subjected to normalization first for each microarray by multiplication of the Cy5 channel with a balance coefficient that set its median gene signal value equal to that for the Cy3 channel. The balance coefficient values were 1.07 for ⌿⑀RACK, 0.77 for G␣q, 0.52 for CSQ, and 1.50 for CN. Genes whose expression increased or decreased in any one of the four transgenic models were pooled into a group of dynamically regulated genes. The selection criterion was gene expression greater than 1.7-fold induced or repressed from the mean of genes within that region of the scattergram, equaling 2 standard deviations removed from the mean. The high correlation value for the bulk of the unchanged genes allowed for relatively fine differences to be detected. Expression pattern clusters were defined by subjecting the log 2 transformed relative differential expression data set to K-means and hierarchical tree clustering algorithms as implemented in the GeneSpring program (Silicon Genetics). The hierarchical tree analysis was performed using a minimum distance value of 0.001, separation ratio of 0.5, and the standard correlation distance definition. This hierarchical tree structure was used to suggest the optimal group number for K-means clusters, and it was empirically confirmed that the major patterns were detected. The minimal cluster number to accommodate all major patterns was 10, although several clusters were quite similar (example, sets D and E).
Northern analysis. Northern blot analysis was performed using standard methodology and formaldehyde/agarose gels in which 3 g of poly(A)
ϩ mRNA was loaded per lane. Each lane represented RNA from four to six different hearts. Blots were probed with 32 P-labeled (random priming) cDNAs obtained from Incyte which correspond exactly to the DNA targets on the GEM microarrays. RNA dot blots were performed as previously described (4, 14) using 2 g total RNA per dot. Blots were probed with 32 P-labeled antisense oligonucleotides specific for the indicated genes (14) .
RESULTS

Cardiac poly(A)
ϩ RNA from each transgenic model (8-10 ventricles) along with that from paired nontransgenic siblings was simultaneously submitted to Genome Systems for GEM microarray hybridization. The four models studied represent a continuum of hypertrophy phenotypes. ⌿⑀RACK mice, in which a transgenically expressed synthetic octapeptide selectively activates protein kinase C-⑀ (7), has increased myocardial mass, normal cardiomyocyte size, and normal ventricular function, i.e., "physiological hypertrophy" (17) . CSQ mice, in which the calcium binding protein CSQ is overexpressed, have mild ventricular hypertrophy and contractile depression (21) , whereas CN and G␣ q overexpressors have more pronounced ventricular hypertrophy and contractile depression (4, 18) . Contractile depression in the latter three models classifies them as "pathological hypertrophy" (although in the current studies no mice were studied in a state of heart failure). A standard screening of cardiac gene expression by RNA dot blot analyses demonstrated a range of molecular abnormalities in the four models (Fig. 1A) , corresponding to those noted in previously published descriptions (4, 17, 18, 21) . Individual DNA microarray results for each of the four transgenic models are shown in Fig. 1B , with hybridization intensity for the transgenic mice plotted vertically, vs. that for the nontransgenic siblings from each model on the horizontal axis. Increased gene expression in the transgenic model is indicated by deviation above the line of unity slope and a red shift, whereas a decrease in gene expression in the transgenic is indicated by downward deviation and a blue shift. Optimal hybridization for each of the four experiments is indicated by gene expression data that consistently fit along the line of slope unity. A high degree of reproducibility between experiments was shown by comparative analysis of the 88 internal standards included in each microarray, the results for which were highly correlated between all four differential hybridizations (data not shown).
Since the Incyte GEM microarrays contain numerous genes that are not significantly expressed in cardiac tissue, the gene expression profiles were initially refined by deleting genes with absolute expression levels in the lower quartile of both nontransgenic and transgenic mice for all four models. This low-signal region of the microarray experiment is also more susceptible to minor distortion effects that prevent linear normalization (see, for example, the falling tails of CSQ and ⌿⑀RACK; Fig. 2B ). Several genes tested from this region failed to show signal in poly(A) ϩ Northern analyses (data not shown). Thus 887 sequence tags, or ϳ10% of total number of sequences (representing those in the bottom left quadrant of the expression profiles shown in Fig. 1 ), were excluded from subsequent comparative analysis. It is apparent from examination of the differential expression data in Fig. 1 that the gene Fig. 1 . A: gene expression profiles of four transgenic mouse hypertrophy models. RNA dot blot analysis of four transgenic mouse hypertrophy models; c, control; ⌿⑀R, ⌿⑀RACK (protein kinase C-⑀ activator); CSQ, calsequestrin; CN, calcineurin; ANP, atrial natriuretic peptide; ␤MHC, ␤-myosin heavy chain; ␣sk actin, ␣-skeletal actin. B: microarray analysis of the four hypertrophy models. For each mouse, hybridization signal intensity is plotted logarithmically on the vertical axis for transgenic and on the horizontal axis for nontransgenic. Relative differential expression (transgenic signal/nontransgenic signal) is indicated by red-to-blue shading and displacement from the line of unity. expression profile was most "abnormal" in the G␣ q model, with abnormal being defined as genes with a relative differential expression value greater than ϩ1.7 or less than Ϫ1.7 (corresponding to Ͼ2 standard deviations from the mean). This threshold level of differential gene expression was applied across all four experiments. An initial profiling of genes in this manner showed that the number of differentially regulated genes was greater in G␣ q than CN or CSQ models and that expression of relatively few genes was altered in ⌿⑀RACK ( Fig. 2A) . Interestingly, when the gene expression data for each model were compared as shown in Fig. 2B , no genes were found to be regulated in common among the four hypertrophy models. Furthermore, only one gene, ANP, was coregulated in the three pathological hypertrophy models. Thus a conserved multigene hypertrophy expression program was not detected among the genes represented on the GEM microarrays.
An advantage of comparing gene expression in genetic forms of cardiac hypertrophy, where variously perturbed signaling events cause hypertrophy via different signaling mechanisms, is the potential to identify model-specific molecular events, i.e., unique molec- Fig. 3 . Hierarchical analysis of gene expression patterns in mouse hypertrophy models: grouping of expressed sequences into gene clusters based on expression trends between models. The hierarchical tree is depicted leading to individual gene expression values (red/blue) for the four models. Gene clusters are color coded and assigned alphabetical designation A through I, except for the seven genes upregulated only in ⌿⑀RACK (group 0). Groups D-G form a superfamily of genes highly expressed in G␣q. Group H, consisting of genes expressed in direct proportion to phenotypic severity, is magnified below for clarity. The red/blue color scale for differential expression is identical to that in Fig. 1 . ANP is indicated.
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Physiol Genomics • VOL 6 • www.physiolgenomics.org at Penn State Univ on February 23, 2013 http://physiolgenomics.physiology.org/ ular features specific for each form of hypertrophy. Therefore, despite the absence of an obvious "hypertrophy gene program," we sought to test the hypothesis that model-specific gene expression changes could provide insight into the pathophysiology of their respective phenotypes and perhaps of myocardial hypertrophy in general. To detect such patterns, hierarchical tree and K-means clustering algorithms were applied to the expression profiles of the pool of 276 genes that exhibited dynamic regulation among any of the four models. As depicted in Fig. 3 , patterns of gene expression existed which could be grouped into clusters reflecting both shared and individual genetic profiles across the four models. Nine of the ten expression profiles are shown in Fig. 4 (not shown is the cluster of seven uniquely upregulated genes in ⌿⑀RACK, group O; see Table 1 ). The approximate biophysical correlates to these mathematical subgroups are as follows: group A, genes expressed greatly more in CSQ than other models; group B, genes downregulated in CN and/or G␣ q ; group C, genes downregulated in CSQ; groups D-G, a superfamily of genes upregulated in G␣ q , with subgroups based on patterned expression in other models; group H, genes whose expression increases in direct proportion to phenotypic severity of the four models; and group I, genes expressed more in CN than other models. Gene annotations for each hierarchical cluster are in Table 1 , and Northern blot analyses of select genes are shown in Fig. 5 , confirming the results of microarray experiments. As expected (and serving as an important internal control), the microarrays detected mRNAs corresponding to the transgenes for each model; CSQ was in group A, CN in group I, and G␣ 11 , which is closely related to G␣ q , was in group E (G␣ q is not represented on these GEM microarrays.)
Simple comparative analyses of the genes in the four hypertrophy models upregulated by more than ϫ1.7 failed to identify any commonly expressed genes (see Fig. 2B ). However, application of the K-means clustering-algorithm allowed detection of a group (group H) of Fig. 4 . Expression of genes from various hierarchical clusters in mouse hypertrophy models. The color coding and alphabetical designations are same as Fig. 3 . Individual gene differential expression is depicted for each model. Vertical scale is log2 of relative differential expression. Gene designations for each cluster are in Table 1 .
Physiol Genomics • VOL 6 • www.physiolgenomics.org defined genes with a continuum of expression that paralleled the phenotype, i.e., genes whose expression correlated with severity of pathological hypertrophy (Table 1) . ANP, as expected, is in this grouping, along with procollagen type I ␣1 and expressed sequence tags (ESTs) highly similar to smooth muscle ␣-actinin and the Down syndrome candidate gene recently described as a putative negative regulator of CN (19) . Upregulated genes specific to the four hypertrophy models included, in addition to the transgenes themselves (and a large number of unidentified sequence tags), several unique functional gene groups with likely pathophysiological relevance. Most striking was the segregation of upregulated apoptosis genes into subgroups D, E, and F of the superset of genes upregulated in G␣ q . These apoptosis genes include caspase 1 (group D), Fas-associated factor 1 and a Bcl-2/E1B interacting protein (group E), and apoptosis inhibitor 1 (group F) (see Fig. 5 ). Importantly, of the four transgenic models studied herein, only the G␣ q overexpressor is predisposed to cardiomyocyte apoptosis (1) . In contrast, several upregulated protein phosphatases segregated into group I, and included, in addition to CN, the ␣-catalytic subunit of protein phosphatase 3 and protein phosphatase X, suggesting a role for regulated phosphatases in the CN model. Several individual genes also showed intriguing model-specific expression patterns; the renin 1 gene in group E, the A kinase anchor proteins AKAP-4 and -95 genes in groups E and G, and the osteoblast-specific factor 2 (OSF-2) gene in group I. 
DISCUSSION
The stated purpose of this study was to identify a defined set of genes that are commonly regulated among four genetic models of cardiac hypertrophy, anticipating that these genes would encompass those molecular events necessary for, or critical to, the hypertrophy process. Therefore, the relative expression of ϳ8,800 expressed sequences was compared in multiple genetically manipulated mouse models exhibiting increased myocardial mass and including both cardiomyocyte hypertrophy and hyperplasia. Surprisingly, not a single assayed gene was coregulated among all four models, and for the three models of pathological hypertrophy, only ANP was coordinately upregulated. A reciprocal observational approach of defining genes that were uniquely regulated in one model or another proved to be more illuminating than identifying conserved genes, especially after cluster analysis was used to identify trends of gene expression across the hypertrophy phenotypic spectrum. Thus an important outcome of these comparative experiments may be a renewed focus on model-specific genetic events as determinants of unique phenotypic features.
The notion of deemphasizing common or highly conserved genetic events in hypertrophy is further supported when the present results are compared with other recently reported gene expression profiles of cardiac hypertrophy. Hwang et al. (12) identified transcript profiles of hypertrophied human hearts by comparative analysis of cDNA libraries, and their 10 strongest candidates for differential expression included ANP, brain natriuretic peptide (BNP), and ␣-skeletal actin. These three genes were also in the top 10 list of genes reported by Friddle et al. (9) as being upregulated during angiotensin II and isoproterenol induction of cardiac hypertrophy in mice. In the current studies, these genes were all members of the group H gene cluster which correlated closely with the pathological severity of the cardiac phenotype. In fact, these genes have long been recognized as molecular markers of cardiomyocyte hypertrophy both in vivo and in vitro when assayed by Northern or RNA dot blot analysis (2-4, 6, 10, 11, 17, 18, 21, 23; see Fig. 1A ).
Thus the genes that tend to be expressed in common among various different forms of hypertrophy are not, in this case, molecular keys that unlock the hypertrophic process, but rather appear to be nonspecific transcriptional adaptations to myocardial contractile dysfunction or cardiac injury (24) .
Taking the opposite approach, that of identifying transcriptional features that distinguished the four models, was more revealing. Perhaps predictably, the absolute number of genes regulated in the hypertrophy models corresponded approximately with the severity of the observed pathology. Thus, in ⌿⑀RACK where it is thought that postnatal cardiomyocyte hyperplasia results in normally functioning, but enlarged heart (17), only seven genes fell outside the established limits of "normality." In contrast, in the G␣ q model of cardiomyocyte hypertrophy, which develops contractile dysfunction and a predisposition to apoptosis (4, 7, 20) , a large number of genes were strongly regulated. It is worthwhile noting that it is impossible to determine from these data which genes are regulated as direct consequence of G␣ q signaling vs. those genes that are regulated indirectly as a consequence of contractile depression. It is interesting, however, that in previous reports of physiological "rescue" of the G␣ q phenotype by superimposed overexpression of ␤ 2 -adrenergic receptors (8) or ⌿⑀RACK (26), ANP and ␣-skeletal actin expression were not normalized and ␤MHC gene expression remained very high. This suggests a direct effect of G␣ q signaling on these genetic markers.
Perhaps the most striking and potentially physiologically meaningful observation from these studies is the delineation of a previously undescribed apoptosis gene program in G␣ q overexpressors. G␣ q mice are uniquely susceptible to apoptotic cardiomyocyte death, with resulting progression from nonfailing hypertrophy to dilated cardiomyopathy (1). This apoptotic degeneration has been described in vivo in G␣ q overexpressors with high levels of transgene expression (compound heterozygous G␣ q mice), in a peripartum cardiomyopathy (1), and after aortic banding (5, 20) . Furthermore, adenoviral transfection of mutationally activated G␣ q into cultured neonatal rat cardiomyocytes causes apoptosis (1) . The increased expression of a caspase, a fas effector and a Bcl-2 interacting protein described herein for G␣ q mice, is likely to contribute to the characteristic apoptotic proclivity of this model. In this regard, it is worthwhile noting that the mice used for these genetic analyses were nonfailing, nonapoptotic G␣ q overexpressors in which apoptosis [assessed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) labeling] is no greater than nontransgenic controls (1, 5) . It is also intriguing that phosphatase genes were uniquely upregulated in the CN model. Since CN is itself a phosphatase, increased expression of protein phosphatases X and 3 suggests a certain degree of coordinated regulation between these three phosphatases. In contrast to the current studies, a previous transcript profiling of CN and pressure overload hypertrophy mice did not report upregulation of phosphatases (13) . Furthermore, whereas we observed significant upregulation of OSF-2, this and other genes were not identified in CN mice, even though they were detected in pressure overload hypertrophy in this prior study (13) . These differences may reflect our selection of 18-day-old CN mice, i.e., the early hypertrophic phase, as opposed to older CN mice in which progression to heart failure is already advanced (18) . Another interesting observation in the current study is the upregulation of mouse skeletal LIM protein and another gene exhibiting homology to titin, specifically in CSQ. Since both of those are sarcomeric proteins, their increased expression may provide important cytoskeletal support for this model, such that hypertrophy does not progress to failure, even over the long term (L. Kranias, unpublished observations).
Although the power of gene expression profiling by the use of DNA microarrays is great, the application of this technology is still in its infancy, and there are technical, intellectual, and economic limitations to these types of studies. First, annotation of the expressed sequence library at this date is such that only approximately half of the sequences have been related to specific genes, although the database is constantly being updated. Second, the number of sequences assayed (ϳ8,800), although substantial, represents only a fraction of the total number of genes expressed in the heart. Furthermore, many of the putative cDNAs on the microarrays no doubt represent genes not expressed to any significant extent in the normal or perturbed heart. For this study, which really represents a first pass without microarray replicates, to increase data trust, we excluded from analysis those genes whose absolute expression levels in both the nontransgenic and transgenic arrays from all four models was in the lower quartile. Clearly, however, much work needs to be done before the entire cardiac "transcriptome" can be assayed using these techniques. In addition, we believe that microarray data should be reviewed using multiple quality measures of the hybridized array, and all potentially significant findings should be confirmed by additional quantitative approaches such as Northern blots, nuclease protection, or internally controlled RT-PCR.
In conclusion, this comparative analysis of gene expression profile of four genetic models of hypertrophy has failed to define a common hypertrophy gene expression program, but rather identifies specific mRNA profile changes likely to represent either mediators or adaptive responses by the heart to specific individual genetic perturbations. Regarding a widely conserved "hypertrophy gene program," it is likely that such a genetic program does not exist and that myocardial hypertrophy, as a universal response to numerous different hemodynamic, toxic, injurious, or genetic stimuli, exhibits molecular characteristics that reflect its original stimulus. Our studies suggest that unique genetic characteristics of hypertrophy, such as upregulated apoptosis gene expression in G␣ q overexpressors, can be important phenotypic determinants and are therefore attractive targets for experimental manipulation and therapeutic modification. As additional types of multi-gene comparisons are applied to other disease models, we expect that expression clusters will suggest both etiologic classification and the selection and optimization of therapeutic strategies.
